Form 4: Elanco Director Equity Awards Announced
Insider Transaction Report
Elanco Animal Health Inc. reports on equity awards granted to its non-employee directors, including deferred stock units and restricted stock units.
Summary
- Paul Herendeen, a Director at Elanco Animal Health Inc., reported transactions on May 21, 2026.
- Herendeen acquired 4,678 deferred stock units as a pro-rated annual equity award.
- Herendeen also acquired 12,196 restricted stock units as an annual equity award.
- These awards are part of the company's compensation for its non-employee Board of Directors.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports on standard director compensation practices rather than financial performance or strategic shifts.
Positives
- Director Paul Herendeen received equity awards, indicating continued investment and alignment with the company's performance.
- The awards are structured as both deferred stock units and restricted stock units, offering a mix of long-term and performance-based incentives.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it pertains to director equity awards.
Industry Context
StockSavvy.ai notes that the granting of equity awards to directors is a common practice in the animal health industry to align executive and board interests with shareholder value and to attract and retain talent.
Stakeholder Impact
- Shareholders: The equity awards align director interests with long-term shareholder value, potentially leading to better governance and strategic decisions.
- Employees: While not directly impacted, such awards can signal a company's commitment to incentivizing its leadership, which may indirectly influence employee morale and retention.
- Management: The awards serve as a form of compensation and incentive for the reporting person and other non-employee directors.
Key Dates
| Date | Description |
|---|---|
| 05/21/2026 | Transaction Date for equity awards |
| 05/26/2026 | Signature Date |
Keywords
Elanco Animal Health, Form 4, SEC Filing, Equity Awards, Director Compensation, Deferred Stock Units, Restricted Stock Units, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.